.Return on Assets (ROA) since 2005
Difficulty: Beginner
Calculation
Bristol-Myers Squibb Co., ROA, long-term trends, calculation
| ROA | = | 100 | × | Net earnings attributable to BMS1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2005 | % | = | 100 | × | ÷ | ||
| Dec 31, 2006 | % | = | 100 | × | ÷ | ||
| Dec 31, 2007 | % | = | 100 | × | ÷ | ||
| Dec 31, 2008 | % | = | 100 | × | ÷ | ||
| Dec 31, 2009 | % | = | 100 | × | ÷ | ||
| Dec 31, 2010 | % | = | 100 | × | ÷ | ||
| Dec 31, 2011 | % | = | 100 | × | ÷ | ||
| Dec 31, 2012 | % | = | 100 | × | ÷ | ||
| Dec 31, 2013 | % | = | 100 | × | ÷ | ||
| Dec 31, 2014 | % | = | 100 | × | ÷ | ||
| Dec 31, 2015 | % | = | 100 | × | ÷ | ||
| Dec 31, 2016 | % | = | 100 | × | ÷ | ||
| Dec 31, 2017 | % | = | 100 | × | ÷ |
1 USD $ in millions
Source: Based on data from Bristol-Myers Squibb Co. Annual Reports
Comparison to Competitors
Bristol-Myers Squibb Co., ROA, long-term trends, comparison to competitors
| Bristol-Myers Squibb Co. | Abbott Laboratories | AbbVie Inc. | Allergan PLC | Amgen Inc. | Biogen Inc. | Celgene Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2005 | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Dec 31, 2006 | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Dec 31, 2007 | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Dec 31, 2008 | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Dec 31, 2009 | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Dec 31, 2010 | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Dec 31, 2011 | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Dec 31, 2012 | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Dec 31, 2013 | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Dec 31, 2014 | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Dec 31, 2015 | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Dec 31, 2016 | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Dec 31, 2017 | % | % | % | % | % | % | % | % | % | % | % | % | % |
Source: Based on data from Bristol-Myers Squibb Co. Annual Reports
Comparison to Pharmaceuticals & Biotechnology Sector
Bristol-Myers Squibb Co., ROA, long-term trends, comparison to Pharmaceuticals & Biotechnology sector
| Bristol-Myers Squibb Co. | Pharmaceuticals & Biotechnology | |
|---|---|---|
| Dec 31, 2005 | % | % |
| Dec 31, 2006 | % | % |
| Dec 31, 2007 | % | % |
| Dec 31, 2008 | % | % |
| Dec 31, 2009 | % | % |
| Dec 31, 2010 | % | % |
| Dec 31, 2011 | % | % |
| Dec 31, 2012 | % | % |
| Dec 31, 2013 | % | % |
| Dec 31, 2014 | % | % |
| Dec 31, 2015 | % | % |
| Dec 31, 2016 | % | % |
| Dec 31, 2017 | % | % |
Source: Based on data from Bristol-Myers Squibb Co. Annual Reports
Comparison to Health Care Industry
Bristol-Myers Squibb Co., ROA, long-term trends, comparison to Health Care industry
| Bristol-Myers Squibb Co. | Health Care | |
|---|---|---|
| Dec 31, 2005 | % | % |
| Dec 31, 2006 | % | % |
| Dec 31, 2007 | % | % |
| Dec 31, 2008 | % | % |
| Dec 31, 2009 | % | % |
| Dec 31, 2010 | % | % |
| Dec 31, 2011 | % | % |
| Dec 31, 2012 | % | % |
| Dec 31, 2013 | % | % |
| Dec 31, 2014 | % | % |
| Dec 31, 2015 | % | % |
| Dec 31, 2016 | % | % |
| Dec 31, 2017 | % | % |
Source: Based on data from Bristol-Myers Squibb Co. Annual Reports
